研究業績

一般社団法人JBCRG学会発表

2016年


Duration of fasting before taking lapatinib is associated with skin toxicity in neoadjuvant treatment of HER2 positive breast cancer: A cohort study from JBCRG-16/Neo-LaTH


Moe Tsuda, Hiroshi Ishiguro, Naoko Toriguchi, Norikazu Masuda, Hiroko Bando, Oogami Masahiro, Honma Masato, Satoru Shimizu, Naohito Yamamoto, Katsumasa Kuroi, Yasuhiro Yanagita, Toshimi Takano, Satoshi Morita, Masakazu Toi


2016.12 SABCS Poster San Antonio, Texas

Analysis of tumor infiltrating lymphocytes in HER2-positive primary breast cancer treated with neoadjuvant lapatinib and trastuzumab: The NeoLath study (JBCRG-16)


Kosuke Kawaguchi, Eiji Suzuki, Tatsuki R Kataoka, Masahiro Hirata, Shinji Ohno, Hiroko Bando, Hiroshi Ishiguro, Kenichi Inoue, Naohito Yamamoto, Katsumasa Kuroi, Satoshi Morita, Norikazu Masuda, Masakazu Toi, Japan Breast Cancer Research Group (JBCRG)


2016 ASCO Poster

PRECIOUS: A randomized, open-label phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients who were previously treated with pertuzumab, trastuzumab, and chemotherapy (JBCRG-M05).


Yutaka Yamamoto, Hiroji Iwata, Takayuki Ueno, Masahiro Kashiwaba, Naruto Taira, Masato Takahashi, Hiroshi Tada, Koichiro Tsugawa, Tatsuya Toyama, Naoki Niikura, Fumitaka Hara, Tomomi Fujisawa, Tetsuhiro Yoshinami, Shigehira Saji, Toshimi Takano, Norikazu Masuda, Satoshi Morita, Masakazu Toi, Shinji Ohno.


2016 ASCO Poster

Efficacy study of sequential therapy with anthracycline, taxane, and eribulin in patients with HER2-negative locally advanced breast cancer (JBCRG-17).


Naoto Kondo, Yoshinori Ito, Ippei Fukada, Shoichiro Ohtani, Masaya Hattori, Eriko Tokunaga, Nobuki Matsunami, Kohjiro Mashino, Taijiro Kosaka, Masahiko Tanabe, Daisuke Yotsumoto, Kosho Yamanouchi, Masataka Sawaki, Masahiro Kashiwaba, Hidetaka Kawabata, Katsumasa Kuroi, Satoshi Morita, Shinji Ohno, Masakazu Toi, Norikazu Masuda


2016 ASCO Poster

フルベストラントの長期奏効群を探索する多施設共同後方視コホート研究;JBCRG-C06 Safari試験


服部正也、川口英俊、増田慎三、中山貴寛、青儀健二郎、阿南敬生、伊藤良則、大谷彰一郎、佐藤信昭、佐治重衡、徳永えり子、中村清吾、長谷川善枝、藤澤知巳、山口美樹、山下年成、山本豊、森田智視、大野真司、戸井雅和


第24回 日本乳癌学会学術集会 厳選口演1(薬物療法)

HER2陰性進行再発乳癌に対するベバシズマブとパクリタキセル併用療法の観察研究(中間報告;JBCRG-C05)


中村力也、近藤直人、山本豊、山城大泰、柏葉匡寛、高橋將人、唐宇飛、津川浩一郎、成井一隆、玉城研太朗、吉波哲大、大谷彰一郎、甲斐裕一郎、高野利実、柳田康弘、森田智視、大野真司、戸井雅和


第24回 日本乳癌学会学術集会 パネルディスカッション3 (乳癌分子標的薬剤)

周術期トラスツズマブ治療歴を有する再発乳癌におけるトラスツズマブ投与の観察研究(JBCRG-C02)


澤木正孝、山城大泰、増田慎三、奥村恭博、高野利実、徳永えり子、齊藤毅、相良安昭、山崎弘資、保野慎治、森田智視、大野真司、戸井雅和


第24回 日本乳癌学会学術集会 厳選口演1 (薬物療法)

Search for appropriate treatment strategy using fulvestrant for postmenopausal ER-positive advanced or recurrent breast cancer patients in Japan (JBCRG-C06; Safari)


Hidetoshi Kawaguchi, Norikazu Masuda, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Yoshinori Ito, Shoichiro Ohtani, Nobuaki Sato, Shigehira Saji,Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Miki Yamaguchi, Toshinari Yamashita, Yutaka Yamamoto, Shinji Ohno, Masakazu Toi


2016 EBCC Poster

Prospective observational cohort study of bevacizumab combined with paclitaxel as the first- or second-line chemotherapy for locally advanced or metastatic breast cancer (Study JBCRG-C05: B-SHARE)


Naoto Kondo, Yutaka Yamamoto, Hiroyasu Yamashiro, Masahiro Kashiwaba, Rikiya Nakamura, Masato Takahashi, Uhi Toh, Koichiro Tsugawa, Kazutaka Narui, Kentaro Tamaki, Tetsuhiro Yoshinami, Shoichiro Ohtani, Yuichiro Kai, Toshimi Takano, Yasuhiro Yanagita, Satoshi Morita, Masakazu Toi, Shinji Ohno


2016 EBCC Poster

任意団体JBCRG 研究業績